ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Juno acquires RedoxTherapies

by Ann M. Thayer
July 25, 2016 | APPEARED IN VOLUME 94, ISSUE 30

Juno Therapeutics has acquired RedoxTherapies for $10 million in cash and potential milestone payments. With the deal comes vipadenant, a small-molecule adenosine A2A receptor antagonist that has the potential to inhibit immunosuppressive pathways in cancer. Juno intends to test the molecule in combination with its engineered T-cell candidates. Only a few days before announcing the acquisition, Juno was allowed to restart a Phase II leukemia clinical trial of its lead product candidate, JCAR015. FDA had halted the trial when two patients died after the addition of another drug to the treatment regimen.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment